Doxycycline Dose-dependently Inhibits MMP-2-Mediated Vascular Changes in 2K1C Hypertension

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 5, 2011, Pages 318-325

  Guimaraes, Danielle A ^a   Rizzi, Elen ^a   Ceron, Carla S ^a   Oliveira, Alisson M ^a   Oliveira, Diogo M ^a   Castro, Michele M ^a   Tirapelli, Carlos R ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GELATINASE A;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HYPERTENSION; HYPERTROPHY; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; ENZYME INHIBITORS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, WISTAR; UP-REGULATION; VASODILATION;

RATTUS;

EID: 79954524108     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00656.x     Document Type: Article

References (37)

1. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346-59.
2. Safar ME, London GM, Asmar R, Frohlich ED. Recent advances on large arteries in hypertension. Hypertension 1998;32:156-61.
3. Lerman LO, Chade AR. Atherosclerotic process, renovascular disease and outcomes from bench to bedside. Curr Opin Nephrol Hypertens 2006;15:583-7.
4. Textor SC. Renovascular hypertension update. Curr Hypertens Rep 2006;8:521-7.
5. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
6. Sluijter JP, de Kleijn DP, Pasterkamp G. Vascular remodeling and protease inhibition--bench to bedside. Cardiovasc Res 2006;69:595-603.
7. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-24.
8. Yasmin SW, McEniery CM, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
9. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
10. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 2005;45:432-7.
11. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2007;292:H2438-48.
12. Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 2004;109:1041-7.
13. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007;50:212-8.
14. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 2008;591:224-30.
15. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008;198:320-31.
16. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010;29:194-201.
17. Lee HM, Ciancio SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75:453-63.
18. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
19. Yaras N, Sariahmetoglu M, Bilginoglu A, Aydemir-Koksoy A, Onay-Besikci A, Turan B et al. Protective action of doxycycline against diabetic cardiomyopathy in rats. Br J Pharmacol 2008;155:1174-84.
20. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
21. Tessone A, Feinberg MS, Barbash IM, Reich R, Holbova R, Richmann M et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 2005;19:383-90.
22. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003;38:1376-83.
23. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003;108:1487-92.
24. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-321.
25. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
26. Rizzi E, Castro MM, Fernandes K, Barbosa F Jr, Arisi GM, Garcia-Cairasco N et al. Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. Arch Toxicol 2009;83:439-49.
27. Dao HH, Lemay J, de Champlain J, deBlois D, Moreau P. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 2001;19:1965-73.
28. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005;38:410-4.
29. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005;344:147-9.
30. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007;40:119-23.
31. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009;46:1298-307.
32. Garcia RA, Go KV, Villarreal FJ. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 2007;300:159-69.
33. Griffin MO, Jinno M, Miles LA, Villarreal FJ. Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol Cell Biochem 2005;270:1-11.
34. Vinet L, Rouet-Benzineb P, Marniquet X, Pellegrin N, Mangin L, Louedec L et al. Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. Am J Physiol Heart Circ Physiol 2008;295:H352-60.
35. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010;160:77-87.
36. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 2002;35:923-9.
37. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.